Trainee presence during endobronchial ultrasound increases complications

The presence of a trainee during endobronchial ultrasound (EBUS) may have negative implications, including increased procedure time and complications.

Researchers from the University of Calgary retrospectively reviewed 607 EBUS procedures, of which a was present for 512.

Significant differences were seen when a trainee was present vs when no trainee was present for procedure length (58.32 vs 37.69 min) and for the dose of propofol used (178.28 vs 137.11 mg).

In addition, more complications were seen in the trainee group (24 vs 1).

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Hormonal therapy for transsexualism safe and effective

23 hours ago

Hormonal therapy for transsexual patients is safe and effective, a multicenter European study indicates. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

Royalty Pharma lets Elan takeover bid expire

Jun 18, 2013

Royalty Pharma has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.

FDA approves new silicone breast implants

Jun 17, 2013

(HealthDay)—MemoryShape breast implants have been approved by the U.S. Food and Drug Administration for breast augmentation in women 22 and older, and for breast reconstruction, the FDA said Friday.

User comments

More news stories

Validating maps of the brain's resting state

Kick back and shut your eyes. Now stop thinking. You have just put your brain into what neuroscientists call its resting state. What the brain is doing when an individual is not focused on the outside world ...

No danger of cancer through gene therapy virus

In fall 2012, the European Medicines Agency (EMA) approved the modified adeno-associated virus AAV-LPL S447X as the first ever gene therapy for clinical use in the Western world. uniQure, a Dutch biotech company, had developed ...

Antioxidant shows promise in Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.